At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Gumarontinib Combined With Third-generation EGFR-TKI in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Amplification Following EGFR-TKI Treatment Failure.
In Brief
A Phase 2 clinical trial evaluating gumarontinib and third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib) for Non-small Cell Lung Cancer. Not yet recruiting, targeting 91 participants.
Detailed Summary
This study evaluated the efficacy and safety of gumarontinib combined with third-generation EGFR-TKI in the treatment of locally advanced or metastatic NSCLC with MET amplification after first-line EGFR-TKI failure, without limiting the type of third-generation EGFR-TKI. The study was divided into 2 cohorts: Cohort 1 included patients with MET amplification after third-generation EGFR-TKI first-line therapy resistance, and cohort 2 included patients with MET amplification after first-generation EGFR-TKI first-line therapy resistance.
Study Details
Timeline
Interventions
300 mg , qd ,po, expect 6 months.
According to the actual situation of patients. Take as recommended, expect 6 months.